| NASDAQ (usa) |
|
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
| DAX (german) |
|
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Calliditas Therapeutics AB (publ) (PINK: CLTEF)
CLTEF Technical Analysis
5
| As on 2nd Jan 2026 CLTEF STOCK Price closed @ 0.55 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.95 & Strong Sell for SHORT-TERM with Stoploss of 3.90 we also expect STOCK to react on Following IMPORTANT LEVELS. |
CLTEFSTOCK Price
| Open | 0.27 | Change | Price | % |
| High | 0.55 | 1 Day | 0.27 | 96.43 |
| Low | 0.27 | 1 Week | -0.33 | -37.50 |
| Close | 0.55 | 1 Month | -3.10 | -84.93 |
| Volume | 500 | 1 Year | -2.15 | -79.63 |
| 52 Week High 11.25 | 52 Week Low 0.00 | ||||
PINK USA Most Active Stocks
| VNUE | 0.00 | % |
| NTRR | 0.00 | % |
| HMBL | 0.00 | % |
| INKW | 0.00 | % |
| TXGE | 3316.21 | 2.69% |
| UBQU | 0.00 | % |
| ECOX | 0.00 | % |
| AURI | 0.00 | % |
| VGTL | 0.00 | % |
| UMAV | 0.00 | % |
PINK USA Top Gainers Stocks
PINK USA Top Losers Stocks
| CLTEF Daily Charts |
CLTEF Intraday Charts |
Whats New @ Bazaartrend |
CLTEF Free Analysis |
|
|
CLTEF Important Levels Intraday
| RESISTANCE | 1.09 |
| RESISTANCE | 0.92 |
| RESISTANCE | 0.81 |
| RESISTANCE | 0.70 |
| SUPPORT | 0.40 |
| SUPPORT | 0.29 |
| SUPPORT | 0.18 |
| SUPPORT | 0.01 |
CLTEF Forecast March 2026
| 4th UP Forecast | 8.74 |
| 3rd UP Forecast | 6.11 |
| 2nd UP Forecast | 4.49 |
| 1st UP Forecast | 2.87 |
| 1st DOWN Forecast | -1.77 |
| 2nd DOWN Forecast | -3.39 |
| 3rd DOWN Forecast | -5.01 |
| 4th DOWN Forecast | -7.64 |
CLTEF Weekly Forecast
| 4th UP Forecast | 9.70 |
| 3rd UP Forecast | 6.77 |
| 2nd UP Forecast | 4.95 |
| 1st UP Forecast | 3.14 |
| 1st DOWN Forecast | -2.04 |
| 2nd DOWN Forecast | -3.85 |
| 3rd DOWN Forecast | -5.67 |
| 4th DOWN Forecast | -8.60 |
CLTEF Forecast2026
| 4th UP Forecast | 22.33 |
| 3rd UP Forecast | 15.34 |
| 2nd UP Forecast | 11.03 |
| 1st UP Forecast | 6.71 |
| 1st DOWN Forecast | -5.61 |
| 2nd DOWN Forecast | -9.93 |
| 3rd DOWN Forecast | -14.24 |
| 4th DOWN Forecast | -21.23 |
Calliditas Therapeutics AB (publ) ( PINK USA Symbol : CLTEF )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
CLTEF Other Details
| Segment | EQ | |
| Market Capital | 768898112.00 | |
| Sector | Healthcare | |
| Industry | Biotechnology | |
| Offical website | > echo $website ; ?> | |
CLTEF Address
![]() |
||
CLTEF Latest News
CLTEF Business Profile
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. The company's lead product candidate is Nefecon, a oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) was founded in 2004 and is headquartered in Stockholm, Sweden. Address: Kungsbron 1, C8, Stockholm, Sweden, 111 22
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service

